Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials

Chu Luan Nguyen1,2*, Lawrence J. Oh1, Eugene Wong1, Joe Wei1 and Michael Chilov1

Abstract

Background: To evaluate the relative efficacy and safety of anti-vascular endothelial growth factor (anti-VEGF) agents for the treatment of neovascular age-related macular degeneration (AMD).

Methods: Systematic literature review identifying RCTs comparing anti-VEGF agents to another treatment published before June 2016. Efficacy assessed by mean change in best corrected visual acuity (BCVA) and central macular thickness (CMT) from baseline at up to 2 years followup. Safety assessed by proportions of patients with death, arteriothrombotic and venous thrombotic events, and at least one serious systemic adverse event at up to 2 years of followup.

Results: Fifteen RCTs selected for meta-analysis (8320 patients). Two trials compared pegaptanib, and three trials compared ranibizumab versus control. Eight trials compared bevacizumab with ranibizumab. Two trials compared aflibercept with ranibizumab. There were no significant differences between bevacizumab and ranibizumab for BCVA at 1 or 2 years (weighted mean difference = −0.57, 95% CI −1.55 to 0.41, \(P=0.25\) and weighted mean difference = −0.76, 95% CI −2.25 to 0.73, \(P=0.32\), respectively). Ranibizumab was more effective in reducing CMT at 1 year (weighted mean difference = 4.49, 95% CI 1.13 to 7.84, \(P=0.009\)). Risk ratios comparing rates of serious systemic adverse events at 1 and 2 years were slightly out of favour for bevacizumab. Aflibercept compared with ranibizumab demonstrated similar mean change in BCVA, reduction in CMT, and safety at 1 year.

Conclusions: Bevacizumab and ranibizumab had equivalent efficacy for BCVA, while ranibizumab had greater reduction in CMT and less rate of serious systemic adverse events. Aflibercept and ranibizumab had comparable efficacy for BCVA and CMT. This provides information to balance comparable effects on vision and risk of adverse events between anti-VEGF agents.

Keywords: Anti-vascular endothelial growth factor, Neovascular age-related macular degeneration, Meta-analysis, Randomized controlled trials

* Correspondence: chuluannguyen@gmail.com
1 University of Sydney, Sydney, NSW 2006, Australia
2 Royal North Shore Hospital, Reserve Rd, St Leonards, NSW 2065, Australia

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Current mainstay treatment for neovascular age-related macular degeneration (nAMD) is intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents, which have been demonstrated to be effective at reducing fluid in the retina and regression of the new vessels [1–4]. The first Food and Drug Administration (FDA) approved anti-VEGF agent, pegaptanib, is not currently used because of the better visual outcomes from ranibizumab (Lucentis, Genentech Inc.), bevacizumab (Avastin, Genentech Inc.), and aflibercept (Eylea, Regeneron Pharmaceuticals, Inc.) [4–7]. Ranibizumab was FDA approved for the treatment of nAMD in 2006. Its efficacy and safety were demonstrated in two major trials, ANCHOR and MARINA [8–10]. Bevacizumab is used off-label to treat nAMD. Multiple trials have demonstrated comparable efficacy and safety between ranibizumab and bevacizumab [4, 11–24]. Aflibercept is a newer agent, with FDA approval in 2011, for the treatment of nAMD. It has been demonstrated to have comparable efficacy and safety compared to ranibizumab in the VIEW1 and VIEW2 trials [5, 25–27]. Similar to aflibercept, is conbercept (Chengdu Kanghong Biotech Co. Ltd.) which was licensed in China in 2013 and there is a single reported phase 2 trial [28].

To the author’s knowledge, existing meta-analyses of randomized controlled trials (RCTs) comparing the efficacy and safety of anti-VEGF agents in patients with nAMD, have included up to 12 trials in their comparisons [4, 5, 20, 29–31]. Such meta-analyses have been limited to the types of anti-VEGF agents evaluated. As new trials and longer-term results are available, synthesis and meta-analysis of current data will assist ophthalmologists and patients when they decide among treatment options. The objectives were to evaluate the relative efficacy and safety of all intravitreal anti-VEGF agents that are available compared with another treatment for nAMD, and in particular when compared to each other.

Methods

Inclusion and exclusion criteria

Articles were considered for inclusion in the meta-analysis if the study design was a RCT, the population was nAMD, and the intervention was anti-VEGF treatment (pegaptanib, ranibizumab, bevacizumab, aflibercept or conbercept) compared to another treatment or each other. All trials followed patients for at least 1 year, and outcomes at two years of treatment were also included when available. The analysis was limited to 2 years of followup given that the individual RCTs had limited followup.

Studies in which different doses of one anti-VEGF agent were compared with each other, with no control or comparator were excluded. Studies in which anti-VEGF agents were used in combination with other treatments were excluded. Conference abstracts and full reports without raw data available, letters, reviews, duplicate publications and studies not available in English were excluded.

Search strategy to identify eligible studies

A systematic literature review with searches of CENTRAL (The Cochrane Library 2016, Issue 4), Ovid MEDLINE (January 1946 to June 2016), EMBASE (January 1974 to June 2016), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/). The final search was performed on June 2016 (Appendix 1).

Types of effect estimates

Efficacy was assessed by the mean change in best corrected visual acuity (BCVA) and in central macular thickness (CMT) from baseline at 1 and 2 years of follow up. Safety was assessed based on the proportions of patients with death, arteriothrombotic and venous thrombotic events, and at least one serious systemic adverse event at 1 and 2 years of follow up. This study conducted meta-analyses of results by anti-VEGF agent, combining different doses and regimens of the same agent evaluated in the individual trials.

Selection of studies, data extraction and qualitative summary

Two review authors independently assessed the titles and abstracts found through the electronic searches (C. L.N. and L.I.O). Disagreement was settled with a third reviewer (E.W.). Two review authors independently extracted study characteristics, such as information on study methods, participants, interventions, efficacy and safety outcomes, and funding resources. The review authors contacted the authors of RCTs for data on outcomes in the individual trials when the information was not available in published form. One author entered data into Review Manager (RevMan, version 5.3), and a second author verified the data entry at a later date. Two review authors independently assessed the study quality. With the RCTs the authors used the risk of bias tool recommended by the Cochrane Collaboration as per methods outlined in the Cochrane Handbook for Systematic Reviews of Interventions [32]. Potential sources of bias in the following different domains were critically assessed: sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors, incomplete outcome data, selective outcome reporting, and other sources of bias. For each domain, the authors judged whether the risk of bias of that domain was high,
low, or unclear. Authors of RCTs were contacted for information to adequately assess a study.

### Statistical analysis

Quantitative data were recorded using Review Manager (RevMan, version 5.3). For continuous variables, the weighted mean difference was measured. For dichotomous variables, the risk ratios (RR) were measured. These were reported with a 95% confidence interval (CI), and \(P < 0.05\) was statistically significant on the test for overall effect. Statistical heterogeneity was assessed based on the \(\chi^2\) test, \(I^2\) statistic and the overlap of CIs in the forest plots. A \(\chi^2\) \(P\) value of < 0.05 had significant statistical heterogeneity and an \(I^2\) statistic of greater than 50% or more had substantial statistical heterogeneity. Clinical and methodological heterogeneity among studies was assessed by comparing the study populations, interventions, and methods of each study [33]. A random-effects model was utilized if there was heterogeneity between studies. Otherwise, a fixed effects model was used. The methodology used for this meta-analysis was adapted from previous meta-analyses for consistency [4, 20].

### Sensitivity analysis

Sensitivity analyses were planned to be performed to assess the impact of studies graded as having a high risk of bias on any parameter or industry funding. Following an assessment of the data collected, it was determined that these analyses were not needed because studies within each meta-analysis did not differ based on these factors.

### Results

#### Characteristics of included studies and quality assessment

A total of 8087 articles were identified and of these 8038 were initially rejected. The 49 remaining articles were assessed for eligibility. Twenty-four studies were excluded after full-text assessment: 16 studies were not RCT, 7 studies were dose-response studies where no control or comparator arm was part of the study, and 5 studies compared combination therapies in which treatment groups received the same anti-VEGF therapy. Twenty-five articles remained and for the included trials that used the same cohort of patients, the latest articles were included giving 17 studies [6, 9, 10, 12, 14, 16, 17, 19, 24, 25, 34–38] (Fig. 1).

#### Risk of bias assessment

There were 17 studies that met the inclusion criteria with 15 studies involving 8320 patients included in the meta-analysis. Two trials were not included in the meta-analysis due to insufficient data available [34, 37]. The characteristics of the included studies and risk of bias assessment are summarized in Table 1 and Fig. 2. Overall the included studies were at low risk of bias.

### Allocation

Reports from 12 of the 15 studies described methods of random sequence generation that were judged to confer a low risk of bias. The methods used in the VIEW1, VIEW2, and Subramanian 2010 trials were not described in sufficient detail to assess its risk of bias.

### Masking

Most of the included studies were judged to be at low risk of performance and detection bias. An exception was the Sacu 2009 study which was an open-label study with no form of masking utilised. In the CATT 2011 and Biswas 2011 studies personnel and outcome assessors were masked. Participants in the CATT 2011 study initially were masked to the drug but may have become aware of the treatment assignments due to billing records. In this way participants were not completely blinded. In the Biswas 2011 study, it was not reported if participants were masked. In the remaining 13 studies, study participants, personnel, and outcome assessors were masked.

### Incomplete outcome data

In all trials, small numbers of participants missed the planned follow-up or were not treated in accordance with the randomized treatment assignment. Losses to followup were evenly balanced across treatment groups among the included studies. Most trials included in this review analysed the data using methods designed to overcome loss of information due to missed follow-up such as the last-observation-carried-forward method.

### Selective reporting

With the exception of the Biswas 2011 study, protocols or clinical trial registrations were identified for the other 14 included studies. Seven of these 14 trials were judged to be free of reporting bias based on the consistency between study outcomes defined in the protocols and clinical trial registrations and those reported in the publications.

### Other potential sources of bias

Trial sponsorship and financial interests of investigators were considered as other potential sources of bias. ANCHOR 2006, MARINA 2006, PIER 2008, and VISION 2004 were sponsored by pharmaceutical companies marketing the anti-VEGF agents. The VIEW1 and VIEW2 trials on aflibercept were assessed to be at low risk of bias for most domains except that both trials were sponsored by the manufacturer of aflibercept and hence were assessed as at high risk of bias. Given the potential conflict of interest in manufacturer-sponsored trials there is a potential interest of the community to disregard a difference of efficacy and safety of anti-VEGF agents.
Sample size and power
Each included RCT had reported power calculations of at least 80% with their sample size, except for the Subramanian 2010 study which had power of 79%, and the Biswas 2011 study which did not report power calculations [34, 35]. With a power of 80% and the number of participants collected in this meta-analysis, ability to detect a difference in VA and CMT, at a two-sided 5% significance level was a minimum meaningful difference to detect of 1.42 letters and 14.34 μm respectively.

Efficacy analysis
Pegaptanib versus control
The VISION 2004 study involved two RCTs. The mean difference in change in BCVA from baseline between the combined pegaptanib groups versus the control group was 6.72 letters (95% CI 4.43 to 9.01, \( P < 0.00001 \)) at 1 year. Patients treated with pegaptanib lost 7 letters fewer than patients in the control group. Optical Coherence Tomography (OCT) was not used in the VISION 2004 study, and hence CMT outcomes were not measured. Two year outcomes were not analysed as the trial crossed over.

Ranibizumab versus control
The three trials involving 1322 patients demonstrated that patients treated with ranibizumab read 18 letters more at the 1 year follow up (weighted mean difference = 17.80, 95% CI 15.95 to 19.65, \( P < 0.00001 \), \( I^2 = 0 \)), and 20 letters more at the two-year follow up than patients in the control groups (weighted mean difference = 20.11, 95% CI 18.08 to 22.15, \( P < 0.00001 \), \( I^2 = 0 \)) (Appendix 2). No data on CMT was available in the three included trials comparing ranibizumab with control.
Bevacizumab versus control
There was insufficient data available to analyze the difference in mean changes in BCVA and CMT between treatment groups.

Bevacizumab versus ranibizumab
For the analyses of bevacizumab versus ranibizumab, groups of the same drug type regardless of dosing regimen were combined. Hence the bevacizumab and ranibizumab groups include both monthly and as needed dosing regimens.

Seven studies involving 2825 patients reported the mean change in CMT at 1 year followup, and the results demonstrated that ranibizumab was more effective in reducing CMT (weighted mean difference = -4.49, 95% CI 1.13 to 7.84, \( P = 0.009 \)), with no heterogeneity. The results of the 3 studies involving 1538 patients for mean change in CMT at two-year followup, demonstrated no significant difference between bevacizumab and ranibizumab (weighted mean difference = 10.86, 95% CI -5.00 to 26.72, \( P = 0.18 \)), with no heterogeneity (Fig. 4).

Aflibercept versus ranibizumab
Two trials comprising of 2412 patients treated with aflibercept and ranibizumab, demonstrated comparable gains in BCVA at 1 year followup (weighted mean difference = -0.15, 95% CI -1.47 to 1.16, \( P = 0.82 \), \( I^2 = 0 \)) (Appendix 3).

Similarly, aflibercept and ranibizumab demonstrated comparable reduction in CMT at 1 year followup (weighted mean difference = -4.94, 95% CI -15.48 to 5.61, \( P = 0.36 \), \( I^2 = 0 \)) (Appendix 4). The two-year efficacy outcomes were unable to be included in the meta-analysis as they were combined when reported. At two

---

**Table 1** Characteristics of included studies

| Study       | Location                                                                 | Treatment groups                                      | Followup, months | Number of patients | Age, years |
|-------------|---------------------------------------------------------------------------|------------------------------------------------------|------------------|-------------------|------------|
| Vision 2004 [6] | United States, Canada, Austria, Belgium, Czech Republic, Denmark, France, Germany, Hungary, Israel, the Netherlands, Poland, Portugal, Spain, Switzerland, UK, Brazil, Chile, Colombia, and Australia | Pegatanib and photocoagulation                       | 12               | 904/304a         | 75/77a     |
| Anchor 2006 [9] | United States, France, Germany, Hungary, Czech Republic, and Australia    | Ranibizumab and photocoagulation                     | 24               | 280/143b         | 76.7/77.8b |
| Marina 2006 [10] | United States                                                              | Ranibizumab and photocoagulation                     | 24               | 478/238b         | 77/77b     |
| Pier 2008 [36] | United States                                                              | Ranibizumab and photocoagulation                     | 24               | 121/63b          | 79/78b     |
| ABC 2010 [34] | United Kingdom                                                             | Bevacizumab and photocoagulation                     | 12               | 65/66c           | 79/81c     |
| Saku 2009 [37] | Austria                                                                    | Bevacizumab and photocoagulation                     | 12               | 14/14c           | 78/78c     |
| CATT 2011 [12] | United States                                                              | Bevacizumab and ranibizumab                         | 24               | 586/599d         | 79.7/78.8d |
| Ivan 2013 [14] | United Kingdom                                                             | Bevacizumab and ranibizumab                         | 24               | 296/314d         | 77.8/77.7d |
| Gefal 2013 [35] | France                                                                     | Bevacizumab and ranibizumab                         | 12               | 191/183d         | 79.6/78.7d |
| Manta 2013 [16] | Austria                                                                    | Bevacizumab and ranibizumab                         | 12               | 154/163d         | 76.7/77.6d |
| Subramanian 2010 [38] | United States                                                        | Bevacizumab and ranibizumab                         | 12               | 15/17d           | 78/80d     |
| Biswas 2011 [24] | India                                                                     | Bevacizumab and ranibizumab                         | 18               | 50/54d           | 64.4/63.5d |
| Lucas 2015 [18] | Norway                                                                    | Bevacizumab and ranibizumab                         | 24               | 213/218d         | 62/78d     |
| BRAMD 2016 [19] | Netherlands                                                                | Bevacizumab and ranibizumab                         | 12               | 161/166d         | 79/78d     |
| View 1 [25] | United States and Canada                                                   | Aflibercept and ranibizumab                         | 24               | 911/304d         | 78/78d     |
| View 2 [25] | Europe, the Middle East, Asia-Pacific, and Latin America                  | Aflibercept and ranibizumab                         | 24               | 913/291d         | 74/73d     |

\(a\)Pegatanib group/photocoagulation group
\(b\)Ranibizumab group/photocoagulation group
\(c\)Bevacizumab group/photocoagulation group
\(d\)Bevacizumab group/ranibizumab group
\(e\)Aflibercept group/ranibizumab group
years the mean change in BCVA from baseline was 7.2 letters and 7.9 letters in the aflibercept and ranibizumab groups respectively, and this was not statistically significant. Data on outcomes for reduction in CMT at two years were not available.

Safety analysis

Pegaptanib versus control
Rates of systemic serious adverse events did not differ significantly between pegaptanib and control intervention at 1 year followup. Estimated relative risk ratio of at least 1 systemic serious adverse event for pegaptanib compared to control at 1 year was 1.25 (CI 0.93 to 1.70, \( P = 0.14 \)).

Ranibizumab versus control
Rates of death and arteriothrombotic events in ranibizumab and control groups did not differ significantly at 1 year or 2 years (Appendices 5 and 6).

Bevacizumab versus control
There was insufficient data available to analyze safety between treatment groups.

Bevacizumab versus ranibizumab
There were no significant differences between bevacizumab and ranibizumab in terms of rates of death, arteriothrombotic events, or venous thrombotic events at 1 year or 2 years, and no statistical heterogeneity was identified between the studies. However, bevacizumab had a significantly higher rate of at least 1 serious systemic adverse event in comparison with ranibizumab at 1 year and 2 years (RR = 1.18, 95% CI 1.01 to 1.39, \( P = 0.04 \), \( \bar{I}^2 = 0 \), and RR = 1.15, 95% CI 1.02 to 1.30, \( P = 0.02 \), \( \bar{I}^2 = 40\% \)) (Figs. 5 and 6).

Aflibercept versus ranibizumab
At 1 year followup, there were no significant differences between aflibercept and ranibizumab in terms of rates of death, arteriothrombotic events, or venous thrombotic events (Appendix 7). However, the numbers for these adverse events were small. Adverse event data from VIEW1 and VIEW2 trials were not available for analysis of two-year outcomes due to data from both studies being combined. Following two years, 3.3% (60/1824) of patients treated with aflibercept experienced an arteriothrombotic event compared to 3.2% (19/595) of patients treated with ranibizumab (RR 1.03, 95% CI 0.62 to 1.71). The risk of any serious systemic adverse event was similar between aflibercept and ranibizumab groups at two-year follow-up (RR 0.98, 95% CI 0.83 to 1.15).

Discussion
Fifteen RCTs including 8320 patients were of good methodological quality and demonstrated the beneficial effect of anti-VEGF therapy on visual and anatomical outcomes in the treatment of nAMD. Potential sources of bias in these trials were assessed and parameters considered included selection bias, performance bias, detection bias, attrition bias, and reporting bias. Six of 15
trials, one study of pegaptanib [6], three studies comparing ranibizumab with controls [9, 10, 36], and two studies comparing aflibercept with ranibizumab were sponsored by pharmaceutical companies that marketed the anti-VEGF agents under investigation [25, 26]. Overall the included trials were found to be at low risk for all categories of bias, hence there was high level evidence for the results of this meta-analysis.

Patients treated with either pegaptanib or ranibizumab, had greater mean change in BCVA at 1 year compared with patients who received control intervention [6–10, 36, 39]. OCT was not used in these trials, precluding CMT outcomes to be measured in this meta-analysis. The safety profile of pegaptanib and ranibizumab were comparable to control intervention.

Two studies involving 159 total patients compared intravitreal bevacizumab injections with control treatment [34, 37]. There was insufficient data to analyze the difference in mean changes in BCVA between treatment groups. Also, there were no measures of variability to allow meta-analyses of mean change in CMT at 1 year in either of these trials.

Eight trials compared bevacizumab with ranibizumab. Bevacizumab and ranibizumab demonstrated similar
efficacy for improvement in BCVA at 1 year and 2 years [11–19, 23, 24]. Both anti-VEGF agents also significantly reduced CMT, but ranibizumab was more effective in reducing CMT after 1 year of treatment. This superiority diminished after two years of followup [13–15]. Rates of death and arteriothrombotic events were equivalent between bevacizumab and ranibizumab. However, systemic serious adverse events were significantly more frequent in patients treated with bevacizumab compared with ranibizumab. Venous thrombotic adverse events were more frequent in patients treated with bevacizumab, but this was not statistically significant.

The combined data of 2412 patients demonstrated that aflibercept provided similar mean change in BCVA and CMT at 1 year from baseline in comparison with ranibizumab. Although safety profiles for aflibercept and ranibizumab were similar, the numbers of these adverse events were not adequate in the VIEW1 and VIEW2 trials to provide power for precise evaluation of safety outcomes [25, 26]. Nevertheless, analyses of the
available data demonstrate that aflibercept may be equally effective and safe. Aflibercept may offer the added potential benefit of fewer injections needed to achieve similar results compared to bevacizumab and ranibizumab. In the VIEW trials, treatment schedules were fixed for the first year (every four- or eight-weekly injections), and then changed to as needed dosing in the second year. Patients in the eight-weekly aflibercept group achieved visual and anatomic improvements similar to those in the four-weekly ranibizumab and four-weekly aflibercept groups, but with a mean of 5 fewer injections over 2 years. This has potential for reduced treatment burden and risks that are associated with frequent injections. However, in real-world clinical practice, a treat-and-extend regimen is more commonly used.

The review is limited in that publication bias could not be fully eliminated. Comparative studies of ranibizumab, bevacizumab, and aflibercept as used in current clinical practice for nAMD will be useful to demonstrate whether the frequency of injection and the long-term costs associated with use of each anti-VEGF agent are different. Also, larger trials would be needed to provide precise estimates of adverse events, as the available clinical trial sample sizes may not have been large enough to detect rare adverse events.

The important findings in this meta-analysis are that of the relative efficacy and safety of anti-VEGF agents when compared with each other. It has been established that anti-VEGF agents are superior to laser photocoagulation, but comparisons of anti-VEGF agents with each other provides useful information. This meta-analysis

---

| Study or Subgroup | Bevacizumab Events Total | Ranibizumab Events Total | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|--------------------------|--------------------------|-----------------------------|
| CATT 2011         | 36 586                   | 32 599                   | 1.15 [0.72, 1.82]           |
| IVAN 2013         | 15 296                   | 15 314                   | 1.06 [0.53, 2.13]           |
| LUCAS 2015        | 15 220                   | 13 221                   | 1.16 [0.56, 2.38]           |
| **Total (95% CI)** | **1102**                 | **1134**                 | **1.13 [0.80, 1.59]**       |
| Total events      | 66 60                    |                          |                             |

Heterogeneity: $\chi^2 = 0.04$, df = 2 ($P = 0.98$); $I^2 = 0$
Test for overall effect: $Z = 0.71$ ($P = 0.48$)

---

| Study or Subgroup | Bevacizumab Events Total | Ranibizumab Events Total | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|--------------------------|--------------------------|-----------------------------|
| CATT 2011         | 29 586                   | 28 599                   | 1.06 [0.64, 1.76]           |
| IVAN 2013         | 10 296                   | 13 314                   | 0.82 [0.36, 1.83]           |
| LUCAS 2015        | 9 220                    | 14 221                   | 0.65 [0.29, 1.46]           |
| **Total (95% CI)** | **1102**                 | **1134**                 | **0.90 [0.61, 1.31]**       |
| Total events      | 48 55                    |                          |                             |

Heterogeneity: $\chi^2 = 1.09$, df = 2 ($P = 0.58$); $I^2 = 0$
Test for overall effect: $Z = 0.57$ ($P = 0.57$)

---

| Study or Subgroup | Bevacizumab Events Total | Ranibizumab Events Total | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|--------------------------|--------------------------|-----------------------------|
| CATT 2011         | 10 586                   | 3 599                    | 3.41 [0.94, 12.32]          |
| IVAN 2013         | 4 296                    | 3 314                    | 1.41 [0.32, 6.27]           |
| LUCAS 2015        | 0 220                    | 3 221                    | 0.14 [0.01, 2.76]           |
| **Total (95% CI)** | **1102**                 | **1134**                 | **1.57 [0.70, 3.55]**       |
| Total events      | 14 9                     |                          |                             |

Heterogeneity: $\chi^2 = 3.93$, df = 2 ($P = 0.14$); $I^2 = 49$
Test for overall effect: $Z = 1.09$ ($P = 0.28$)

---

| Study or Subgroup | Bevacizumab Events Total | Ranibizumab Events Total | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|--------------------------|--------------------------|-----------------------------|
| CATT 2011         | 234 586                  | 190 599                  | 1.26 [1.08, 1.47]           |
| IVAN 2013         | 80 296                   | 81 314                   | 1.05 [0.80, 1.37]           |
| LUCAS 2015        | 64 220                   | 67 221                   | 0.96 [0.72, 1.28]           |
| **Total (95% CI)** | **1102**                 | **1134**                 | **1.15 [1.02, 1.30]**       |
| Total events      | 378 338                  |                          |                             |

Heterogeneity: $\chi^2 = 3.33$, df = 2 ($P = 0.19$); $I^2 = 40$
Test for overall effect: $Z = 2.26$ ($P = 0.02$)

---

Fig. 6 Serious systemic adverse events comparing bevacizumab with ranibizumab at 2 years. M-H, Mantel–Haenszel statistics
demonstrates that bevacizumab and ranibizumab produce comparable benefits in regards to preserving or improving vision. Ranibizumab produces significantly better anatomical outcome but this superior effect diminishes over time. There were no significant differences between the bevacizumab and ranibizumab in terms of rates of death, or arteriothrombotic or venous thrombotic events. However, bevacizumab was slightly out of favour with regards to systemic serious adverse events at 1 and 2 years followup. Increased mortality associated with use of intravitreal bevacizumab in nAMD patients after myocardial infarction (MI) compared to age- and gender-matched post-MI patients with no exposure to any anti-VEGF agent has been reported [40]. Current available data on adverse effects suggest that the safety profile of aflibercept is comparable with that of ranibizumab, however the number of patients who experienced adverse events was small, leading to imprecise estimates of effect sizes. These results are similar to previous meta-analyses on this topic [4, 5, 20, 29–31, 41].

Conclusions
The results of this review indicate effectiveness of anti-VEGF agents in terms of the stability or improvement in VA after 1 and 2 years of treatment. Bevacizumab and ranibizumab had equivalent efficacy for BCVA, while ranibizumab had greater reduction in CMT and less rate of serious systemic adverse events. Aflibercept and ranibizumab had comparable efficacy for BCVA and CMT. The available information on adverse effects with each drug does not suggest a higher incidence of vision-threatening complications with intravitreal anti-VEGF injection compared with control interventions. However, clinical trial data may not be sufficiently powered to detect rare safety outcomes. As RCTs have found little difference in outcomes between ranibizumab, bevacizumab, and aflibercept, a challenge for ophthalmologists and patients with nAMD has been the choice of anti-VEGF agent. This meta-analysis provides information to balance the comparable effects on vision and risk of adverse events between anti-VEGF agents for treatment of nAMD.

Appendix 1
Search Strategy
Full literature search strategy of databases

CENTRAL search strategy
#1 MeSH descriptor Macular Degeneration
#2 MeSH descriptor Retinal Degeneration
#3 MeSH descriptor Neovascularization, pathologic
#4 ((macul* OR retina* OR choroid*:TI) AND (degener* OR neovasc*:TI))
#5 ((macul* OR retina* OR choroid*:AB) AND (degener* OR neovasc*:AB))
#6 maculopath*
#7 (1 OR 2 OR 3 OR 4 OR 5 OR 6)
#8 MeSH descriptor Angiogenesis Inhibitors
#9 MeSH descriptor Angiogenesis Inducing Agents
#10 MeSH descriptor Endothelial Growth Factors
#11 macugen or pegapanib or lucentis or rhufab or rhu fab or ranibizumab or bevacizumab or aflibercept or conbercept
#12 angiogen* or antiangiogen* or neovasculari* or vasculari*
#13 anti-vegf* or anti next vegf
#14 endothelial near growth near factor*
#15 (8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14)
#16 (7 AND 15)

MEDLINE search strategy
1. randomized controlled trial.pt
2. (randomized or randomised).Ab,ti
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1–7
9. exp. animals/
10. exp. humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp. macular degeneration/
14. exp. retinal degeneration/
15. exp. retinal neovascularization/
16. exp. choroidal neovascularization/
17. exp. macula lutea/
18. maculopath$.tw.
19. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
20. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
21. (macula$ adj2 lutea).tw.
22. exp. angiogenesis inhibitors/
23. angiogenesis inducing agents/
24. exp. vascular endothelial growth factors/
25. exp. vascular endothelial growth factors/
26. (anti adj2 VEGF$).tw.
27. (endothelial adj2 growth adj2 factor$).tw.
28. (anti adj1 angiogen$).tw.
29. (macugen$ or pegaptanib$ or lucentis$ or rhufab$ or ranibizumab$ or bevacizumab$ or avastin$ or aflibercept$ or conbercept$).tw.
30. VEGF TRAP$.tw.
31. (AMD or ARMD or CNV).tw.
32. or/13–22
33. exp. angiogenesis inhibitors/
34. angiogenesis inducing agents/
35. endothelial growth factors/
36. vascular endothelial growth factors/
37. (anti adj2 VEGF$).tw.
38. (endothelial adj2 growth adj2 factor$).tw.
39. (anti adj1 angiogen$).tw.
40. (macugen$ or pegaptanib$ or lucentis$ or rhufab$ or ranibizumab$ or bevacizumab$ or avastin$ or aflibercept$ or conbercept$).tw.
EMBASE search strategy
1. exp. randomized controlled trial/
2. exp. randomization/
3. exp. double blind procedure/
4. exp. single blind procedure/
5. random$.tw.
6. or/1–5
(animal or animal experiment).Sh
7. human.sh.
8. 7 and 8
9. 7 not 9
10. 6 not 10
12. exp. clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp. placebo/
16. placebo$.tw.
17. random$.tw.
18. exp. experimental design/
19. exp. crossover procedure/
20. exp. control group/
21. exp. latin square design/
22. or/12–21
23. 22 not 10
24. 23 not 11
25. exp. comparative study/
26. exp. evaluation/
27. exp. prospective study/
28. (control$ or prospectiv$ or volunteer$).Tw.
29. or/25–28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp. retina macula degeneration/
34. exp. retinal degeneration/
35. exp. subretinal neovascularization/
36. maculopath$.tw.
37. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
38. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
39. (macula$ adj2 lutea).tw.
40. (AMD or ARMD or CNV).tw.
41. or/33–40
42. angiogenesis/
43. exp. angiogenesis inhibitors/
44. angiogenic factor/
45. endothelial cell growth factor/
46. monoclonal antibody/
47. vasculotropin/
48. (anti adj2 VEGF$).tw.
49. (endothelial adj2 growth adj2 factor$).tw.
50. (anti adj1 angiogen$).tw.
51. (macugen$ or pegaptanib$ or lucentis$ or rhufab$ or ranibizumab$ or bevacizumab$ or avastin$ or aflibercept$ or conbercept$).tw.
52. VEGF TRAP$.tw.
53. or/42–52
54. 41 and 53
55. 32 and 54
metaRegister of Controlled Trials search strategy
(macular degeneration or AMD or ARMD) and
(macugen or pegaptanib or lucentis or rhufab or ranibizumab or bevacizumab or avastin or aflibercept or conbercept)
ClinicalTrials.gov search strategy
(Macular Degeneration OR AMD OR ARMD) AND
(Macugen OR Pegaptanib OR Lucentis OR rhufab OR ranibizumab OR bevacizumab OR avastin OR aflibercept or conbercept)
ICTRP search strategy
Macular Degeneration OR AMD OR ARMD = Condition AND Macugen OR Pegaptanib OR Lucentis OR rhufab OR ranibizumab OR bevacizumab OR avastin OR aflibercept OR conbercept = Intervention
Appendix 2

**Mean change in BCVA from baseline at 1 year**

| Study or Subgroup   | Ranibizumab Mean | SD   | Total | Control Mean | SD   | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---------------------|------------------|------|-------|--------------|------|-------|--------|-----------------------------------|
| ANCHOR 2006         | 9.9 14.64        | 279  | -9.5 16.4 | 143           | 33.6 | 19.40 | [16.21, 22.59] |
| MARINA 2006         | 6.85 13.57       | 478  | -10.4 16.7 | 238           | 57.1 | 17.25 | [14.80, 19.70] |
| PIER 2008           | -0.89 14.09      | 121  | -16.3 22.3 | 63            | 9.3  | 15.41 | [9.36, 21.46]  |
| Total (95% CI)      | 878              |      |        | 444 100.0%   | 17.80 | [15.95, 19.65] |

Heterogeneity: $\chi^2 = 1.76$, df = 2 ($P = 0.41$); $I^2 = 0$
Test for overall effect: $Z = 18.88$ ($P < 0.00001$)

**Mean change in BCVA from baseline at 2 years**

| Study or Subgroup   | Ranibizumab Mean | SD   | Total | Control Mean | SD   | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---------------------|------------------|------|-------|--------------|------|-------|--------|-----------------------------------|
| ANCHOR 2006         | 9.4 16.37        | 279  | -9.8 17.6 | 143           | 34.5 | 19.20 | [15.73, 22.67] |
| MARINA 2006         | 6.15 18.64       | 478  | -14.9 18.7 | 238           | 54.0 | 20.90 | [18.13, 23.67] |
| PIER 2008           | -2.25 14.94      | 121  | -21.4 21.8 | 63            | 11.5 | 19.15 | [13.14, 25.16] |
| Total (95% CI)      | 878              |      |        | 444 100.0%   | 20.11 | [18.08, 22.15] |

Heterogeneity: $\chi^2 = 0.68$, df = 2 ($P = 0.71$); $I^2 = 0$
Test for overall effect: $Z = 19.37$ ($P < 0.00001$)

Fig. 7 Ranibizumab versus control. Mean change in best corrected visual acuity (in letters) from baseline comparing ranibizumab with control at 1 and 2 years. IV, inverse variance; SD, standard deviation

Appendix 3

**Mean change in BCVA from baseline to year 1**

| Study or Subgroup   | Afibercept Mean | SD   | Total | Ranibizumab Mean | SD   | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---------------------|-----------------|------|-------|------------------|------|-------|--------|-----------------------------------|
| VIEW 1              | 8.57 14.17      | 906  | 8.1 15.3 | 304             | 45.7 | 0.47  | [-1.48, 2.42] |
| VIEW 2              | 0.72 13.73      | 911  | 9.4 13.5 | 291             | 54.3 | -0.68 | [-2.47, 1.11] |
| Total (95% CI)      | 1817            |      |        | 595 100.0%      | -0.15 | [-1.47, 1.16] |

Heterogeneity: $\chi^2 = 0.72$, df = 1 ($P = 0.39$); $I^2 = 0$
Test for overall effect: $Z = 0.23$ ($P = 0.82$)

Fig. 8 Afibercept versus ranibizumab. Mean change in best corrected visual acuity (in letters) from baseline comparing afibercept with ranibizumab at 1 year. IV, inverse variance; SD, standard deviation

Appendix 4

**Mean change in central macular thickness from baseline to year 1**

| Study or Subgroup   | Afibercept Mean | SD   | Total | Ranibizumab Mean | SD   | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---------------------|-----------------|------|-------|------------------|------|-------|--------|-----------------------------------|
| VIEW 1              | -120.19 103.78  | 906  | -116.8 | 109             | 56.8 | -3.39 | [-17.38, 10.60] |
| VIEW 2              | -145.47 115.61  | 911  | -138.5 | 122.2           | 43.2 | -6.97 | [-23.02, 9.08]  |
| Total (95% CI)      | 1817            |      |        | 595 100.0%      | -4.94 | [-15.48, 5.61] |

Heterogeneity: $\chi^2 = 0.11$, df = 1 ($P = 0.74$); $I^2 = 0$
Test for overall effect: $Z = 0.92$ ($P = 0.36$)

Fig. 9 Afibercept versus ranibizumab. Mean change in central macular thickness (μm) from baseline comparing afibercept with ranibizumab at 1 year. IV, inverse variance; SD, standard deviation
### Appendix 5

#### Death

| Study or Subgroup | Ranibizumab Events | Control Events | Total | Weight | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|------------------|--------------------|----------------|-------|--------|-------------------------------|-------------------------------|
| ANCHOR 2006      | 5                  | 2              | 143   | 100.0% | 1.29 [0.25, 6.57]             |                               |
| PIER 2008        | 0                  | 0              | 63    |        | Not estimable                 |                               |
| **Total (95% CI)** | 397                | 206            |       | 100.0% | **1.29 [0.25, 6.57]**         |                               |
| **Total events**  | 5                  | 2              |       |        |                               |                               |

Heterogeneity: Not applicable
Test for overall effect: $Z = 0.31$ ($P = 0.76$)

#### Arteriothrombotic events

| Study or Subgroup | Ranibizumab Events | Control Events | Total | Weight | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|------------------|--------------------|----------------|-------|--------|-------------------------------|-------------------------------|
| ANCHOR 2006      | 5                  | 2              | 143   | 57.3%  | 1.29 [0.25, 6.57]             |                               |
| PIER 2008        | 0                  | 0              | 63    | 42.7%  | 0.18 [0.01, 4.27]             |                               |
| **Total (95% CI)** | 397                | 206            |       | 100.0% | **0.82 [0.21, 3.09]**         |                               |
| **Total events**  | 5                  | 2              |       |        |                               |                               |

Heterogeneity: $\chi^2 = 1.19$, df = 1 ($P = 0.27$); $I^2 = 16$
Test for overall effect: $Z = 0.30$ ($P = 0.76$)

**Fig. 10** Ranibizumab versus control. Serious systemic adverse events comparing ranibizumab with control at 1 year. M-H, Mantel–Haenszel statistics

### Appendix 6

#### Death

| Study or Subgroup | Ranibizumab Events | Control Events | Total | Weight | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|------------------|--------------------|----------------|-------|--------|-------------------------------|-------------------------------|
| ANCHOR 2006      | 8                  | 5              | 143   | 45.1%  | 0.83 [0.28, 2.48]             |                               |
| MARINA 2006      | 11                 | 6              | 236   | 54.9%  | 0.91 [0.34, 2.42]             |                               |
| **Total (95% CI)** | 754                | 379            |       | 100.0% | **0.87 [0.42, 1.81]**         |                               |
| **Total events**  | 19                 | 11             |       |        |                               |                               |

Heterogeneity: $\chi^2 = 0.02$, df = 1 ($P = 0.90$); $I^2 = 0$
Test for overall effect: $Z = 0.37$ ($P = 0.71$)

#### Arteriothrombotic events

| Study or Subgroup | Ranibizumab Events | Control Events | Total | Weight | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|------------------|--------------------|----------------|-------|--------|-------------------------------|-------------------------------|
| ANCHOR 2006      | 9                  | 4              | 143   | 39.7%  | 1.16 [0.36, 3.71]             |                               |
| MARINA 2006      | 18                 | 6              | 236   | 60.3%  | 1.48 [0.60, 3.69]             |                               |
| **Total (95% CI)** | 754                | 379            |       | 100.0% | **1.36 [0.66, 2.77]**         |                               |
| **Total events**  | 27                 | 10             |       |        |                               |                               |

Heterogeneity: $\chi^2 = 0.11$, df = 1 ($P = 0.74$); $I^2 = 0$
Test for overall effect: $Z = 0.83$ ($P = 0.40$)

**Fig. 11** Ranibizumab versus control. Serious systemic adverse events comparing ranibizumab with control at 2 years. M-H, Mantel–Haenszel statistics
## Abbreviations
AMD: Age-related macular degeneration; BCVA: Best-corrected visual acuity; CI: Confidence interval; CMT: Central macular thickness; ICTRP: International Clinical Trials Registry Platform; OCT: Optical Coherence Tomography; PGF: Placental growth factor; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCT: Randomized clinical trial; RR: Relative risk; VEGF: Vascular endothelial growth factor

## Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

## Authors' contributions
CN contributed to the conception of the work; the acquisition and analysis of data for the work; the drafting of the work and revision; and the final approval of the version to be published. LO contributed to the acquisition and analysis of data for the work; the drafting of the work and revision; and the final approval of the version to be published. EW contributed to the acquisition and analysis of data for the work; the drafting of the work and revision; and the final approval of the version to be published. JW contributed to the acquisition and analysis of data for the work; the drafting of the work and revision; and the final approval of the version to be published. MC contributed to the conception of the work; the acquisition and analysis of data for the work; the drafting of the work and revision; and the final approval of the version to be published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

## Ethics approval and consent to participate
Not applicable.

## Competing interests
The authors declare that they have no competing interests.

## Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## References
1. The Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–72.
2. Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115(1):116–26.
3. Bressler SB. Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology. 2009;116:S1–7.
4. Solomon SD, Lindsley K, Vedulla SS, Krystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration (review). Cochrane Database Syst Rev. 2014;8:CD0011346.
5. Sanvar S, Clearfield E, Soliman MK, Sadiq MA, Baldwin AJ, Hanout M, Agarrwal A, Sepah YJ, Do DV, Nguyen QD. Aflibercept for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2016;2:CD011346.
6. Group VISiONVISIONCT. Year 2 efficacy results of 2 randomized controlled clinical trials of Pegaptanib for Neovascular age-related macular degeneration. Ophthalmology. 2006;113:1508–21.

## Appendix 7

### Table 1:风险管理表

| Study or Subgroup | Aflibercept Events Total | Ranibizumab Events Total | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|--------------------------|--------------------------|--------|-------------------------------|
| VIEW 1            | 5                        | 911                      | 1      | 100%                          |
| VIEW 2            | 4                        | 913                      | 1      | 100%                          |
| Total (95% CI)    | 9                        | 1,824                    | 595    | 100%                          |

### Table 2:静脉血栓栓塞性事件

| Study or Subgroup | Aflibercept Events Total | Ranibizumab Events Total | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|--------------------------|--------------------------|--------|-------------------------------|
| VIEW 1            | 5                        | 911                      | 1      | 100%                          |
| VIEW 2            | 4                        | 913                      | 1      | 100%                          |
| Total (95% CI)    | 9                        | 1,824                    | 595    | 100%                          |

### Table 3:动脉血栓栓塞性事件

| Study or Subgroup | Aflibercept Events Total | Ranibizumab Events Total | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|--------------------------|--------------------------|--------|-------------------------------|
| VIEW 1            | 5                        | 911                      | 1      | 100%                          |
| VIEW 2            | 4                        | 913                      | 1      | 100%                          |
| Total (95% CI)    | 9                        | 1,824                    | 595    | 100%                          |

Fig. 12 Aflibercept versus ranibizumab. Serious systemic adverse events comparing aflibercept with ranibizumab at 1 year. M-H, Mantel–Haenszel statistics.

Abbreviations: AMD: Age-related macular degeneration; BCVA: Best-corrected visual acuity; CI: Confidence interval; CMT: Central macular thickness; ICTRP: International Clinical Trials Registry Platform; OCT: Optical Coherence Tomography; PGF: Placental growth factor; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCT: Randomized clinical trial; RR: Relative risk; VEGF: Vascular endothelial growth factor

Availability of data and materials: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions: CN contributed to the conception of the work; the acquisition and analysis of data for the work; the drafting of the work and revision; and the final approval of the version to be published. LO contributed to the acquisition and analysis of data for the work; the drafting of the work and revision; and the final approval of the version to be published. EW contributed to the acquisition and analysis of data for the work; the drafting of the work and revision; and the final approval of the version to be published. JW contributed to the acquisition and analysis of data for the work; the drafting of the work and revision; and the final approval of the version to be published. MC contributed to the conception of the work; the acquisition and analysis of data for the work; the drafting of the work and revision; and the final approval of the version to be published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate: Not applicable.

Competing interests: The authors declare that they have no competing interests.

Publisher’s Note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 16 November 2017 Accepted: 8 May 2018
Published online: 30 May 2018
7. Gragoudas ES, Adams AP, Cunningham ET, Feinsod M, Geyer DR, Group fViSNCT. Pegaptanib for Neovascular age-related macular degeneration. N Engl J Med. 2004;351(12):2805–16.
8. Brown DM, Kaiser PK, Michelis M, Soubrane G, Heier JS, Kim RY, Sip JP, Schneider S, Group rAF. Ranibizumab versus Verteporfin for Neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–44.
9. Brown DM, Michels M, Kaiser PK, Heier JS, Sip JP, Lanctue L, Group AS. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(7):57−65 e55.
10. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, Group rFMS. Ranibizumab for Neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–21.
11. Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3rd, Fine SL. Five-year outcomes with anti-vascular endothelial growth factor treatment of Neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(8):1751–61.
12. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth CA, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–98.
13. Group rCR. Ranibizumab and bevacizumab for Neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–908.
14. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Cullford IA, Reeves BC. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258–67.
15. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomised trial. Ophthalmology. 2012;119(7):399–411.
16. Kriebi J, Schmetterer L, Boltz A, Todd R, Wècei-Markovits V, Egger S, Schönher U, Haas A, Ansari-Shahrezaei S, Bender S, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97:7–11.
17. Berg K, Hadzic E, Gjertsen I, Forsas V, Berger LH, Kinge B, Henschien H, Fossen K, Markovic S, Pedersen TR, et al. Ranibizumab or bevacizumab for Neovascular age-related macular degeneration according to the Lucentis compared to Avastin study treat-and-extend protocol: two-year results. Ophthalmology. 2016;123(1):51−9.
18. Berg K, Pedersen TR, Sandvik L, Bragadottir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122(1):146−52.
19. Schauwvliege AM, D’Amico R, Dickersin K, Kodjikian L, Lindsley K, et al. Systematic review of ranibizumab versus bevacizumab for neovascular age-related macular degeneration: the BRAMD study. PLoS One. 2016;11(5):e0153052.
20. Chen C, Li W, Teo KD, Jiang F, Mao S, Tong Y. Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. Retina. 2015;35:187−93.
21. Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, D’Amico R, Dickersin K, Kodjikian L, Lindsey K, et al. Systematic review of ranibizumab versus bevacizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;9:CD011230.
22. Liu E, Donati S, Virlgi G, Krystolik MG, Krystolik MG. Treatment schedules for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. 2016.
23. Subramanian ML, Ness S, Abedi G, Ahmed E, Daly M, Feinberg E, Bhatia S, Patel P, Nguyen M, Houranieh A. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am J Ophthalmol. 2009;148(6):e875−82 e871.
24. Kiwaisi P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S. Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol. 2011;59(3):191–6.
25. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, et al. Intravitreal aflibercept injection for Neovascular age-related macular degeneration: sixty-nine-sixWeek results of the VIEW studies. Ophthalmology. 2014;121:193−201.
26. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, et al. Intravitreal aflibercept (VEGF trap) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537−48.
27. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF trap. Br J Ophthalmol. 2008;92(5):667−8.
28. Li X, Xu G, Wang Y, Xu X, Liu X, Tang S, Zhang F, Zhang J, Tang L, Wu Q, et al. Safety and efficacy of concomitant in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology. 2014;121(9):1740–7.
29. Ba J, Peng RS, Xu D, Li Y, Shi H, Wang Q, Yu J. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Drug Des Devel Ther. 2015;9:5397−405.
30. Vedula SS, Krystolik MG. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2008;2:CD005139.
31. Thulliez M, Angoulvant D, Pisella PJ, Bejan-Angoulvant T. Overview of systematic reviews and meta-analyses on systematic adverse events included in studies. In: Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions version 510 (updated march 2011) The Cochrane Collaboration, 2011 Available from www.cochrane-handbookorg.
32. Higgins JP, Thompson SG, Deeks JJ, Altman DJ. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
33. Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, et al. Bevacizumab for neovascular age-related macular degeneration (ABC trial): multicentre randomised double dummy study. BMJ. 2010;340:c2459.
34. Kodjikian L, Souied EH, Mimoun G, Mauguet-Fayasse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G, Group GS. Ranibizumab versus bevacizumab for Neovascular age-related macular degeneration: results from the GEFL noninferiority randomized trial. Ophthalmology. 2013;120(11):2300–9.
35. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PREY study year 2. Am J Ophthalmol. 2010;150(3):315−24 e311.
36. Sacu S, Michels S, Prager F, Weigert G, Dunaiovsky G, Reitzenauer W, Prunte C, Schmidt-Erfurth U. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye (Lond). 2009;23(12):2223−7.
37. Subramanian ML, Abedi G, Ness S, Ahmed E, Feinberg M, Daly MK, Houranieh A, Feinberg EB. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye (Lond). 2010;24(1):1708−15.
38. Regillo CD, Brown DM, Abraham P, Yue H, Lanctue L, Schneider S, Shams N. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PREY study year 1. Am J Ophthalmol. 2008;145(2):239−48.
39. Hanhart J, Comanescu SS, Freier-Dror Y, Vinker S. Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis. Graefe’s Arch Clin Exp Ophthalmol. 2010;248:651−63.
40. Thulliez M, Angoulvant D, Pisella PJ, Bejan-Angoulvant T. Overview of systematic reviews and Meta-analyses on systemic adverse events AssociatedWith intravitreal anti–vascular endothelial growth FactorMedication use. JAMA Ophthalmol. 2018;https://doi.org/10.1001/jamaophthalmol.20180002.